GeoVax Announces $6 Million Public Offering to Advance Immunotherapies and Vaccines

GeoVax Labs, Inc., a clinical-stage biotechnology company, has entered into agreements to raise approximately $6 million through a public offering of 9.2 million units, each comprising one share of common stock and warrants, priced at $0.65 per unit. The warrants allow the purchase of up to 18.5 million shares of common stock at the same price, exercisable immediately and valid for five years. Roth Capital Partners is managing the offering, with proceeds intended for working capital and general corporate purposes. The offering, expected to close around July 2, 2025, is part of GeoVax's strategy to advance its portfolio, including a next-generation COVID-19 vaccine and therapies for solid tumor cancers. The offering is made under a registration statement filed with the SEC, with details available on the SEC's website.